Low- and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome

S. R. Marder, T. van Putten, Jim Mintz, M. Lebell, J. McKenzie, P. R. May

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

We evaluated the effectiveness and the side effects of what we defined as low (5-mg) and conventional (25-mg) doses of fluphenazine decanoate administered every two weeks in a double-blind comparison. Subjects were 66 patients who fulfilled DSM-III criteria for schizophrenic disorder. Evaluation of the survival with each dose revealed no significant difference at one year, but significantly better survival was seen with the 25-mg dose (64%) than the 5-mg dose (31%) at two years. There was no significant difference in survival when the clinician was permitted to make a dosage adjustment up to 10 mg in the low-dose group and 50 mg in the higher-dose group when the patient demonstrated evidence of a symptomatic exacerbation. Patients assigned to the higher dose appeared to feel more uncomfortable during the early months of the study, as indicated by significantly higher scores on subscales of the Hopkins Symptom Checklist-90R and higher side effect scores for retardation and akathisia. Implications for clinical practice are discussed.

Original languageEnglish (US)
Pages (from-to)518-521
Number of pages4
JournalArchives of General Psychiatry
Volume44
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Survival
Social Adjustment
Psychomotor Agitation
Checklist
Diagnostic and Statistical Manual of Mental Disorders
Schizophrenia
Therapeutics
fluphenazine depot

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Marder, S. R., van Putten, T., Mintz, J., Lebell, M., McKenzie, J., & May, P. R. (1987). Low- and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome. Archives of General Psychiatry, 44(6), 518-521.

Low- and conventional-dose maintenance therapy with fluphenazine decanoate : Two-year outcome. / Marder, S. R.; van Putten, T.; Mintz, Jim; Lebell, M.; McKenzie, J.; May, P. R.

In: Archives of General Psychiatry, Vol. 44, No. 6, 1987, p. 518-521.

Research output: Contribution to journalArticle

Marder, SR, van Putten, T, Mintz, J, Lebell, M, McKenzie, J & May, PR 1987, 'Low- and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome', Archives of General Psychiatry, vol. 44, no. 6, pp. 518-521.
Marder, S. R. ; van Putten, T. ; Mintz, Jim ; Lebell, M. ; McKenzie, J. ; May, P. R. / Low- and conventional-dose maintenance therapy with fluphenazine decanoate : Two-year outcome. In: Archives of General Psychiatry. 1987 ; Vol. 44, No. 6. pp. 518-521.
@article{c3eb2170f340411a8166d926feda36d6,
title = "Low- and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome",
abstract = "We evaluated the effectiveness and the side effects of what we defined as low (5-mg) and conventional (25-mg) doses of fluphenazine decanoate administered every two weeks in a double-blind comparison. Subjects were 66 patients who fulfilled DSM-III criteria for schizophrenic disorder. Evaluation of the survival with each dose revealed no significant difference at one year, but significantly better survival was seen with the 25-mg dose (64{\%}) than the 5-mg dose (31{\%}) at two years. There was no significant difference in survival when the clinician was permitted to make a dosage adjustment up to 10 mg in the low-dose group and 50 mg in the higher-dose group when the patient demonstrated evidence of a symptomatic exacerbation. Patients assigned to the higher dose appeared to feel more uncomfortable during the early months of the study, as indicated by significantly higher scores on subscales of the Hopkins Symptom Checklist-90R and higher side effect scores for retardation and akathisia. Implications for clinical practice are discussed.",
author = "Marder, {S. R.} and {van Putten}, T. and Jim Mintz and M. Lebell and J. McKenzie and May, {P. R.}",
year = "1987",
language = "English (US)",
volume = "44",
pages = "518--521",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Low- and conventional-dose maintenance therapy with fluphenazine decanoate

T2 - Two-year outcome

AU - Marder, S. R.

AU - van Putten, T.

AU - Mintz, Jim

AU - Lebell, M.

AU - McKenzie, J.

AU - May, P. R.

PY - 1987

Y1 - 1987

N2 - We evaluated the effectiveness and the side effects of what we defined as low (5-mg) and conventional (25-mg) doses of fluphenazine decanoate administered every two weeks in a double-blind comparison. Subjects were 66 patients who fulfilled DSM-III criteria for schizophrenic disorder. Evaluation of the survival with each dose revealed no significant difference at one year, but significantly better survival was seen with the 25-mg dose (64%) than the 5-mg dose (31%) at two years. There was no significant difference in survival when the clinician was permitted to make a dosage adjustment up to 10 mg in the low-dose group and 50 mg in the higher-dose group when the patient demonstrated evidence of a symptomatic exacerbation. Patients assigned to the higher dose appeared to feel more uncomfortable during the early months of the study, as indicated by significantly higher scores on subscales of the Hopkins Symptom Checklist-90R and higher side effect scores for retardation and akathisia. Implications for clinical practice are discussed.

AB - We evaluated the effectiveness and the side effects of what we defined as low (5-mg) and conventional (25-mg) doses of fluphenazine decanoate administered every two weeks in a double-blind comparison. Subjects were 66 patients who fulfilled DSM-III criteria for schizophrenic disorder. Evaluation of the survival with each dose revealed no significant difference at one year, but significantly better survival was seen with the 25-mg dose (64%) than the 5-mg dose (31%) at two years. There was no significant difference in survival when the clinician was permitted to make a dosage adjustment up to 10 mg in the low-dose group and 50 mg in the higher-dose group when the patient demonstrated evidence of a symptomatic exacerbation. Patients assigned to the higher dose appeared to feel more uncomfortable during the early months of the study, as indicated by significantly higher scores on subscales of the Hopkins Symptom Checklist-90R and higher side effect scores for retardation and akathisia. Implications for clinical practice are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0023184229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023184229&partnerID=8YFLogxK

M3 - Article

C2 - 3555385

AN - SCOPUS:0023184229

VL - 44

SP - 518

EP - 521

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 6

ER -